Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6436 USD | +2.22% |
|
-2.10% | -23.38% |
23/05 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
23/05 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.38% | 31.83M | - | - | |
+23.13% | 46.93B | B- | ||
+37.49% | 39.08B | A | ||
-8.73% | 38.48B | B | ||
+28.09% | 31.01B | B | ||
-12.26% | 26.14B | C | ||
+10.57% | 25.88B | B- | ||
+45.05% | 14.15B | B+ | ||
+32.23% | 12.53B | C+ | ||
-6.56% | 11.36B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVGN Stock
- EVGN Stock
- Ratings Evogene Ltd.